Linda R. Mileshkin
Distinguished in Cervical Cancer

Linda R. Mileshkin

305 Grattan St, 
Melbourne, VIC, AU 
Distinguished in Cervical Cancer
305 Grattan St, 
Melbourne, VIC, AU 
OverviewLocationsClinical Research

Overview

Linda Mileshkin practices in Melbourne, Australia. Ms. Mileshkin is rated as a Distinguished expert by MediFind in the treatment of Cervical Cancer. Her top areas of expertise are Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Lung Cancer, and Hysterectomy.

Her clinical research consists of co-authoring 198 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 23 articles and participated in 1 clinical trial in the study of Cervical Cancer.

Gender
Female

Locations

305 Grattan St, Melbourne, VIC 3000, Australia
Other Locations
St Andrews Place, East Melbourne, VIC 8006, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Bintrafusp Alfa
Study Phase: Phase 2

198 Total Publications

Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial.
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial.
Journal: Obstetrical & gynecological survey
Published: October 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Mileshkin's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile